Moderna (MRNA) is back in focus after reporting that its personalized mRNA cancer therapy intismeran achieved primary and key secondary goals in a large Phase 3 melanoma trial, outperforming standard immunotherapy alone.

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.

Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday’s historic 177% rally. The reversal follows a Phase 3 win for Moderna’s personalized cancer vaccine,

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.

In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the mRNA platform and how it quickens vaccine production

Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its growing cancer therapy pipeline.

US pharma giants Moderna and Merck have scored a breakthrough in a vaccine that could allow people with a type of skin cancer to live longer. The companies say their vaccine reduced the risk of recurrence and spread of melanoma,

Moderna MRNA stock fell 20%% to $138, compared with Wednesday’s close of $174.38. The decline followed a more than doubling of the shares on August 19 after Moderna and Merck announced positive results from the Phase 3 INTerpath-001 study of their personalized mRNA cancer vaccine, intismeran autogene.